Breaking News Instant updates and real-time market news.

TSLA

Tesla

$292.16

4.46 (1.55%)

, MU

Micron

$44.00

1.55 (3.65%)

09:08
04/04/19
04/04
09:08
04/04/19
09:08

Fly Intel: Pre-market Movers

HIGHER: TheStreet (TST), up 5% after declaring a $1.77 per share special distribution and announcing 1-for-10 reverse stock split... Tonix Pharmaceuticals (TNXP), up 20% after announcing the expansion of the TNX-102 SL program beyond posttraumatic stress disorder to include Phase 3 development for TNX-102 SL in fibromyalgia... NIO Inc. (NIO), up 2% after Citi analyst Jeff Chung upgraded NIO Inc. to Buy from Neutral and BofA Merrill Lynch upgraded the stock to Neutral from Underperform. UP AFTER EARNINGS: RPM (RPM), up 3%... Simply Good Foods (SMPL), up 2%. LOWER: Tesla (TSLA), down 10% after reporting Q1 deliveries were approximately 63,000 vehicles, which was 110% more than the same quarter last year, but 31% less than last quarter... Aveo Pharmaceuticals (AVEO), down 30% after 21.74M share spot secondary priced at $1.15 per share... Sangamo (SGMO), down 6% after 11M share spot secondary priced at $11.50 per share... Micron (MU), down 4% after Morgan Stanley analyst Joseph Moore downgraded shares to Underweight from Equal Weight, stating that the company's fundamentals have not changed but the stock has rallied. " However, the growing consensus view that earnings will be near a bottom this quarter seems "much too optimistic" to Moore. DOWN AFTER EARNINGS: Office Depot (ODP), down 14%.

TSLA

Tesla

$292.16

4.46 (1.55%)

MU

Micron

$44.00

1.55 (3.65%)

TST

TheStreet

$2.50

0.145 (6.16%)

TNXP

Tonix Pharmaceuticals

$2.33

-0.095 (-3.92%)

NIO

NIO Inc.

$5.27

-0.19 (-3.48%)

RPM

RPM

$59.43

0.32 (0.54%)

SMPL

Simply Good Foods

$23.61

0.93 (4.10%)

ODP

Office Depot

$3.77

0.16 (4.43%)

AVEO

Aveo Pharmaceuticals

$1.03

-0.5 (-32.68%)

SGMO

Sangamo

$11.99

-0.35 (-2.84%)

  • 04

    Apr

  • 04

    Apr

  • 22

    Apr

  • 03

    May

  • 04

    Apr

  • 04

    Apr

TSLA Tesla
$292.16

4.46 (1.55%)

04/04/19
ROTH
04/04/19
NO CHANGE
Target $270
ROTH
Neutral
Roth Capital sees 'busy day' ahead for Tesla investors
Roth Capital analyst Craig Irwin believes Thursday will be a "busy day" for Tesla investors with Elon Musk's court date in front of Judge Nathan, "terrible" deliveries numbers, and mounting questions about cash burn and capital market access. The analyst sees the CEO's antics challenging the SEC as "reckless," and could see similar behavior in court. Cash will be impacted by the weak quarter, so questions on capital market access are important, he added. Irwin reiterates a Neutral rating and s $270 price target on the shares.
04/04/19
WEDB
04/04/19
NO CHANGE
Target $365
WEDB
Outperform
Tesla price target lowered to $365 from $390 at Wedbush
Wedbush analyst Daniel Ives lowered his price target for Tesla to $365 from $390 to reflect lower deliveries and a higher chance of capital raise now on the horizon. The analyst notes that Tesla has reported its Q1 production and delivery numbers as well as the number of vehicles currently in transit to customers. Ives notes that the Street was expecting an apocalyptic quarter and Model 3 deliveries were slightly better than feared by many with 50k Model 3 vehicles the "line in the sand." Nonetheless, the overall number was "clearly rocky" and represents an "air pocket" quarter, he contends. The analyst reiterates an Outperform rating on the shares.
04/04/19
BARD
04/04/19
NO CHANGE
Target $465
BARD
Outperform
Tesla estimates lowered on lower deliveries, margins at Baird
Baird analyst Ben Kallo maintained an Outperform rating and $465 price target on Tesla after Model 3 deliveries came in line with expectations, though Model S and X deliveries both his and consensus estimates. Kallo says a high number of cars in transit at the end of the quarter could impact cash flow, though Tesla indicated it had "sufficient" cash flow. Kallo tells investors in a research note that he is lowering estimates to reflect lower-than-expected deliveries and margins, and now sees Q1 revenue of $4.8B, gross margin of 17.3% and adjusted EPS of (69c), with 2019 revenue of $25.4B, gross margin of 20.1% and adjusted EPS of $3.67.
04/04/19
COWN
04/04/19
NO CHANGE
Target $170
COWN
Underperform
Tesla growth narrative 'looks very suspect' after 'ugly' Q1 report, says Cowen
Cowen analyst Jeffrey Osborne said Tesla's "very weak" Q1 production and delivery results "should make bulls nervous" as he contends that the company's growth narrative "looks very suspect" following the report that deliveries were down 31% and production was cut 11% compared to Q4. Tesla management reiterated "the lowest of its several guidance versions," but Osborne believes that lower range is still very aggressive given low demand for the Model S/X and the company's likely need to manage the Model 3 mix to stay profitable. Osborne keeps an Underperform rating on Tesla shares and lowered his price target on the stock to $170 from $180.
MU Micron
$44.00

1.55 (3.65%)

04/04/19
MSCO
04/04/19
DOWNGRADE
Target $32
MSCO
Underweight
Micron downgraded to Underweight following recent rally at Morgan Stanley
As previously reported, Morgan Stanley analyst Joseph Moore downgraded Micron to Underweight from Equal Weight, stating that the company's fundamentals have not changed but the stock has rallied amid recent optimism as cloud demand has started to come back and a competitor has experienced a "minor product qualification challenge." However, the growing consensus view that earnings will be near a bottom this quarter seems "much too optimistic" to Moore, who sees DRAM remaining oversupplied throughout the year and into next. NAND is closer to a bottom than DRAM, admits Moore, but he sees difficult conditions persisting for NAND through the year as well. He keeps a $32 price target on Micron shares.
04/04/19
MSCO
04/04/19
DOWNGRADE
MSCO
Underweight
Micron downgraded to Underweight from Equal Weight at Morgan Stanley
04/01/19
KEYB
04/01/19
NO CHANGE
KEYB
DRAM monthly contract pricing declined sharply again in March, says KeyBanc
KeyBanc analyst Weston Twigg notes that inSpectrum released its March monthly memory contract pricing this morning, with price declines in line with expectations. The analyst anticipates DRAM price declines to continue through the second half of 2019, though the rate of decline will likely decelerate. Twigg also anticipates NAND bit supply growth to drop below 30% on a year over year basis in the second half of the year due to scaling inefficiencies and limited capacity expansion. Despite near-term demand headwinds in both DRAM and NAND, he continues to anticipate meaningful long-term demand growth as new demand drivers, such as 5G, hyperscale, and edge/endpoint devices, continue to expand. Further, the analyst views the DRAM market as likely healthier and more profitable than NAND over the long run given just three main producers - Micron (MU), Samsung (SSNLF), and SK Hynix -, strong long-term demand drivers, and rational capacity expansion. However, NAND pricing could stabilize sooner than DRAM, and NAND shortages may emerge as early as Q3, he adds.
03/28/19
RBCM
03/28/19
INITIATION
Target $50
RBCM
Outperform
Micron assumed with an Outperform at RBC Capital
RBC analyst Mitch Steves assumed coverage of Micron with an Outperform rating and a price target of $50, saying that while the dynamics in memory demand remain "challenging", the space typically rallies on the "last cut". The analyst contends that investors have correctly assumed negative growth through the end of 2019, but expects more positive data points to emerge exiting Q4 of this year as "smartphones recover" and "data center trends ramp up", with increased memory content in both "soaking up excess supply".
TST TheStreet
$2.50

0.145 (6.16%)

12/06/18
RILY
12/06/18
NO CHANGE
Target $3
RILY
Buy
TheStreet trading below net cash after asset sale, says B. Riley FBR
TheStreet shares are trading below net cash following the sale of its institutional business units for $87.3M, B. Riley FBR analyst Kara Anderson tells investors in a research note. She reiterates a Buy rating on the name with a $3.00 price target.
08/13/18
SPHN
08/13/18
NO CHANGE
Target $11
SPHN
Equal Weight
Zoe's Kitchen 'not immune' to weakness across industry, says Stephens
Stephens analyst Will Slabaugh maintained an Equal Weight rating and $11 price target on Zoe's Kitchen (ZOES) ahead of the company's earnings report on Thursday afternoon, telling investors in a research note that another top-line miss in Q1 and lowered guidance showed that the company is not immune to the general weakness across the industry or within the increasingly competitive fast casual marketplace. While he is optimistic around possible benefits from digital, off-premise and menu innovation, the analyst is concerned that competitive challenges in the fast casual dining sector will weigh on the company's top- and bottom-line int he near-term. The analyst says Restaurant Brands (QSR), Carrols (TST) and Wendy's (WEN) remain his favorite names in quick-service and BJ's Restaurants (BJRI) among casuals.
11/15/18
LSCM
11/15/18
NO CHANGE
Target $3
LSCM
Buy
TheStreet deferred revenue accelerated in Q3, says Lake Street
Lake Street analyst Mark Argento says TheStreet posted "solid" Q3 results as deferred revenue started to accelerate. Strength in business-to-business, specifically BoardEx, along with premium business-to-consumer subscribers continued to drive increased deferred subscription revenue, Argento tells investors in a post-earnings research note. The analyst reiterates a Buy rating on the shares with a $3 price target.
04/04/19
LSCM
04/04/19
NO CHANGE
Target $3
LSCM
Buy
TheStreet distribution 'just right' in size, says Lake Street
TheStreet's $94.3M distribution, equating to $1.77 per share in cash, is "just right" in size, Lake Street analyst Mark Argento tells investors in a research note. The distribution leaves more than enough capital to run the remaining consumer business for the foreseeable future while the company continues to explore strategic alternatives, Argento tells investors in a research note. He believes the move is in the best interest of shareholders. The analyst keeps a Buy rating on TheStreet with a $3 price target.
TNXP Tonix Pharmaceuticals
$2.33

-0.095 (-3.92%)

07/27/18
RILY
07/27/18
DOWNGRADE
Target $1.25
RILY
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Tonix Pharmaceuticals to Neutral and cut his price target for the shares to $1.25 from $8. The downgrade follows Tonix's decision to stop the Phase III Honor study of Tonmya in military-related post-traumatic stress disorder. The stock in morning trading is down 65%, or $2.57, to $1.38.
06/06/18
RILY
06/06/18
INITIATION
Target $8
RILY
Buy
Tonix Pharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started Tonix Pharmaceuticals with a Buy rating and $8 price target. The analyst sees an attractive risk/reward ahead of a potential near-term catalyst for the company's treatment of post-traumatic stress disorder.
07/27/18
ROTH
07/27/18
DOWNGRADE
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
07/27/18
ROTH
07/27/18
DOWNGRADE
Target $1
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded Tonix Pharmaceuticals to Neutral from Buy and lowered his price target to $1 from $6 following "disappointing" results from its interim Phase 3 analysis of Tonmya for the treatment of posttraumatic stress disorder. In a research note to investors, Henry notes that the trial was halted as the primary endpoint did not have adequate separation from placebo on the primary endpoint at week 12. While Henry notes that the data at week 4 of the trial did show separation from placebo for CAPS-5 and Clinical Global Impression - Improvement, he contends that PTSD is a "challenging" therapeutic category, and that although the FDA could allow for a shorter duration endpoint, "we view that as the exception as opposed to the rule." Henry does not expect a rebound in shares pending clarity from the FDA on the future pathway utilizing a shorter endpoint, and says shares are "no longer investable for most" due to an uncertain clinical risk profile and financial risk.
NIO NIO Inc.
$5.27

-0.19 (-3.48%)

03/07/19
GSCO
03/07/19
INITIATION
Target $10.7
GSCO
Buy
NIO Inc. reinstated with a Buy at Goldman Sachs
Goldman Sachs analyst Fei Fang reinstated NIO Inc with a Buy and $10.70 price target. Fang said shares have corrected following Q4 results and sees key drivers that include a light business model, successful premium segment branding, economically constrained competitors, and a large volume opportunity for the ES6.
04/04/19
SBSH
04/04/19
UPGRADE
Target $6.8
SBSH
Buy
Citi upgrades NIO to Buy after 47% selloff since March peak
Citi analyst Jeff Chung upgraded NIO Inc. to Buy from Neutral while lowering his price target for the shares to $6.80 from $7.20. BofA/Merrill this morning also upgraded the shares to Neutral from Underperform. Chung is in part making a valuation call with the shares down 47% since the early-March peak. He also expects a valuation "re-rate" of China's electric vehicle sector. NIO's Q1 shipments beat consensus and ES6 deliveries, which start in early June, should be faster than consensus expects, Chung tells investors in a research note. The analyst also believes NIO's customer base is less price sensitive due to its premium brand positioning. Share of NIO are up 14c to $5.45 in premarket trading.
04/04/19
SBSH
04/04/19
UPGRADE
Target $6.8
SBSH
Buy
NIO Inc. upgraded to Buy from Neutral at Citi
Citi analyst Jeff Chung upgraded NIO Inc. to Buy from Neutral while lowering his price target for the shares to $6.80 from $7.20.
04/04/19
BOFA
04/04/19
UPGRADE
Target $6.2
BOFA
Neutral
NIO Inc. upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Ming Hsun Lee upgraded NIO Inc. to Neutral from Underperform with a price target of $6.20. The shares, after declining 47% from the peak in early March, have now factored in the company's lowered sales volume growth, Lee tells investors in a research note. The analyst views NIO's current valuation as fair and expects its volume sales to grow sequentially in Q2 relative to Q1. The company just launched a six-seater ES8, which should gain some popularity from consumers, says Lee. Further, NIO is arranging more test-drive events in more cities, which the analyst believes should help orders improve.
RPM RPM
$59.43

0.32 (0.54%)

01/07/19
BMOC
01/07/19
NO CHANGE
Target $72
BMOC
Outperform
RPM price target lowered to $72 from $77 at BMO Capital
BMO Capital analyst John McNulty lowered his price target on RPM to $72 after its "modestly disappointing" Q2 results reported on Friday. The analyst says the high raw materials have continued to "negatively impact the margins for the segment", while the weakness in European operations and weather factors weighed on the company's top line. McNulty keeps his Outperform rating on RPM longer term, saying the company's cost cutting efforts are on track and that the stock is "relatively inexpensive".
01/03/19
VERT
01/03/19
DOWNGRADE
VERT
Sell
RPM downgraded to Sell from Hold at Vertical Research
Vertical Research analyst Kevin McCarthy downgraded RPM to Sell from Hold.
12/24/18
12/24/18
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. CarMax (KMX) upgraded to Buy from Neutral at Guggenheim with analyst Ali Faghri citing valuation. 2. Newtek Business (NEWT) upgraded to Outperform from Market Perform at Raymond James. 3. RPM (RPM) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. BlackBerry (BB) downgraded to Sell from Buy at Veritas. 5. Histogenics (HSGX) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth saying the FDA is requiring an additional study with NeoCart. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/24/18
JPMS
12/24/18
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades RPM to Underweight on valuation after 2018 rally
JPMorgan analyst Jeffrey Zekauskas downgraded RPM International to Underweight from Neutral and lowered his price target for the shares to $55 from $60. The stock closed Friday down 79c to $58.38. The analyst cites valuation for the downgrade with the shares up 11% year-to-date. The market is already discounting about half of RPM's three-year cost saving target, Zekauskas tells investors in a research note. RPM shares trade at a premium to peers because of its activist involvement and $290M cost reduction target to be achieved over the fiscal 2020 to 2022 period, says the analyst. He admits, however, that RPM may be capable of achieving a portion, or all, of its targeted cost savings in a low raw material cost environment.
SMPL Simply Good Foods
$23.61

0.93 (4.10%)

10/17/18
10/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Buy at Argus. 2. Principal Financial (PFG) initiated with a Hold at Deutsche Bank. 3. MongoDB (MDB) initiated with an Outperform at Oppenheimer. 4. Simply Good Foods (SMPl) initiated with a Buy at Buckingham. 5. AzurRx BioPharma (AZRX) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/18
BUCK
10/17/18
INITIATION
Target $22
BUCK
Buy
Simply Good Foods initiated with a Buy at Buckingham
Buckingham analyst Eric Larson initiated Simply Good Foods with a Buy and $22 price target citing visible long-term growth supported by whitespace opportunity for Atkins. Larson said Simply's industry leading gross margins and asset-lite model protect its competitive position and allow for "substantial" brand investment.
11/19/18
KING
11/19/18
INITIATION
KING
Buy
Simply Good Foods initiated with a Buy at CL King
07/11/18
RHCO
07/11/18
NO CHANGE
Target $20
RHCO
Buy
Simply Good Foods price target raised to $20 from $16 at SunTrust
SunTrust analyst William Chappell raised his price target on Simply Good Foods to $20 and kept his Buy rating after its Q3 earnings beat and a raise in FY18 sales and EBITDA forecasts. The analyst notes that the company will "continue to see top-line benefits as it invests more in marketing and taps more of the self-directed dieters and 'weight ambivalent' demographics".
ODP Office Depot
$3.77

0.16 (4.43%)

04/01/19
SBSH
04/01/19
UPGRADE
Target $18
SBSH
Neutral
Bed Bath & Beyond upgraded to Neutral from Sell at Citi
Citi analyst Geoff Small upgraded Bed Bath & Beyond (BBBY) to Neutral from Sell and raised his price target for the shares to $18 from $10 after taking over coverage of the name. Citi transferred coverage of Broadlines & Hardlines Retail names to Small. The analyst assumed coverage with Buy ratings on AutoZone (AZO), BJ's Wholesale (BJ), Home Depot (HD), Lowe's (LOW), O'Reilly Automotive (ORLY) and Walmart (WMT). The U.S. consumer remains on "solid footing" amid low unemployment, rising wages, declining gas prices, manageable levels of debt, and elevated consumer confidence, Small tells investors in a research note. However, he points out that we are in the ninth year of the current economic expansion and "the possibility of a macroeconomic slowdown cannot be ignored." The analyst prefers retailers operating in "defensive sectors that are less susceptible to disruption by online competitors," namely auto parts, broadlines and home improvement retail. Small also assumed Advance Auto Parts (AAP), Best Buy (BBY), Costco (COST) and Office Depot (ODP) with Neutral ratings.
AVEO Aveo Pharmaceuticals
$1.03

-0.5 (-32.68%)

02/19/19
PIPR
02/19/19
NO CHANGE
Target $3
PIPR
Overweight
Aveo Pharmaceuticals should be bought on any weakness, says Piper Jaffray
Aveo Pharmaceuticals' full Phase III Tivo-3 data for tivozanib in an oral presentation on Saturday "showed clear advantage" for progression-free survival, overall response rate and safety, but the "immature" overall survival data show a hazard ratio of 1.12, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst believes that with more patients still on tivozanib, the hazard ratio could slip below 1.0 and meet the FDA filing requirement. He recommends buying shares of Aveo on weakness and keeps an Overweight rating on the name with a $3 price target.
03/15/19
03/15/19
NO CHANGE

Baird reiterates Outperform rating on Aveo after Q4 earnings
Baird analyst Madhu Kumar reiterated an Outperform rating and $2 price target on Aveo Pharmaceuticals after the company reported its Q4 earnings report. The analyst said in a research note partially titled "Clinical Basis for TIVO-3 OS Optimism" that he continues to have relative optimism to the Street for Fotivda, and added that a Q4 of 2019 update on TIVO-3 OS was a key potential positive catalyst for the stock.
03/28/19
NATL
03/28/19
INITIATION
NATL
Sell
Aveo Pharma initiated with a Sell, $0 price target at National Securities
National Securities initiated Aveo Pharmaceuticals with a Sell and $0 price target saying recent share appreciation is "totally unwarranted." The firm's analyst expects interim and final Phase 3 overall survival data updates to fail to support a Tivozanib NDA filing.
02/04/19
02/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Aveo Pharmaceuticals (AVEO) downgraded to Neutral from Buy at B. Riley FBR with analyst Harshita Polishetty saying she sees a financing overhang after the FDA recommended against the filing of the company's tivozanib new drug application. 2. BHP Billiton (BHP) downgraded to Underweight from Neutral at JPMorgan while Rio Tinto (RIO) was downgraded to Neutral from Overweight at. 3. SAP (SAP) downgraded to Neutral from Buy at BofA/Merrill. 4. MacroGenics (MGNX) downgraded to Sell from Neutral at Citi with analyst Yigal Nochomovitz saying his re-examination of the prior Phase 1 data underpinning the ongoing Phase 3 SOPHIA trial has led him to revise his base case expectation to a failure for the trial. 5. Okta (OKTA) downgraded to Sector Weight from Overweight at KeyBanc with analyst Rob Owens saying that while the Street clearly anticipates meaningful upside to expectations, he believes many of the upside scenarios render shares fairly valued at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SGMO Sangamo
$11.99

-0.35 (-2.84%)

02/08/19
JEFF
02/08/19
NO CHANGE
Target $23
JEFF
Buy
Jefferies sees opportunity in Sangamo after selloff, drops target to $23
Jefferies analyst Maury Raycroft says his Buy thesis on Sangamo Therapeutics is unchanged following yesterday's update. The analyst lowered his price target for the shares to $23 from $26 and maintains a Buy rating. Sangamo demonstrated successful in vivo editing, Raycroft tells investors in a research note. The analyst has confidence in the company's update, noting Sangamo was able to detect an albumin-IDS mRNA transcript in a liver biopsy aspirate that extracted around 100,000-300,000 cells for analysis. Further, concern about patient six and the transaminitis is likely an overreaction as liver enzyme elevation is consistent across gene therapy programs, adds the analyst. Raycroft sees opportunity in Sangamo shares following yesterday's selloff.
04/02/19
WELS
04/02/19
NO CHANGE
Target $34
WELS
Outperform
Sangamo price target raised to $34 from $24 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.
02/07/19
WELS
02/07/19
NO CHANGE
Target $24
WELS
Outperform
Wells Fargo says buy Sangamo on today's 'overdone' selloff
Wells Fargo analyst Jim Birchenough lowered his price target for Sangamo Therapeutics to $24 from $39 following today's update for in-vivo gene editing in mucopolysaccharidosis type I and II. While overall results are disappointing in terms of markers of sustainable efficacy and suggest further optimization required of gene editing efficiency and delivery, individual patient validation with significant iduronate-2-sulfatase enzyme production in one of two high dose MPSII patients and evidence of enzyme production in MPSI is encouraging, Birchenough tells investors in an intraday research note titled "Over Reaction To In-Vivo Gene Editing Update." The analyst believes Sangamo shares are "oversold" on today's news and recommends buying on the weakness. He maintains an Outperform rating on the name. Sangamo shares in in afternoon trading are down 36%, or $4.28, to $7.74.

TODAY'S FREE FLY STORIES

SSNLF

Samsung

$0.00

(0.00%)

, BTC

Bitcoin

$0.00

(0.00%)

06:37
04/25/19
04/25
06:37
04/25/19
06:37
Periodicals
Samsung plans to develop its own Ethereum-based blockchain, token, TNW reports »

Samsung is planning to…

SSNLF

Samsung

$0.00

(0.00%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$87.75

-2.53 (-2.80%)

06:36
04/25/19
04/25
06:36
04/25/19
06:36
Hot Stocks
Valero says expects to invests about $2.5B of capital in 2019, 2020 »

The Houston alkylation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

BWA

BorgWarner

$43.50

-0.135 (-0.31%)

06:36
04/25/19
04/25
06:36
04/25/19
06:36
Earnings
BorgWarner sees Q2 adj. EPS 99c-$1.05, consensus $1.07 »

Sees Q2 organic sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

VLO

Valero

$87.75

-2.53 (-2.80%)

06:36
04/25/19
04/25
06:36
04/25/19
06:36
Earnings
Valero reports Q1 EPS 34c, consensus 29c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

XRX

Xerox

$33.68

-0.53 (-1.55%)

06:35
04/25/19
04/25
06:35
04/25/19
06:35
Earnings
Xerox raises 2019 adjusted EPS view to $3.80-$3.95 from $3.70-$3.80 »

Consensus for 2019 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

MMM

3M

$219.24

-0.28 (-0.13%)

06:35
04/25/19
04/25
06:35
04/25/19
06:35
Hot Stocks
3M CEO says 'the first quarter was a disappointing start to the year' »

"The first quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

MMM

3M

$219.24

-0.28 (-0.13%)

06:34
04/25/19
04/25
06:34
04/25/19
06:34
Hot Stocks
3M sees FY19 organic local-currency sales growth (1%)-2% »

"3M also updated its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

XRX

Xerox

$33.68

-0.53 (-1.55%)

06:34
04/25/19
04/25
06:34
04/25/19
06:34
Earnings
Xerox reports Q1 adjusted EPS 91c, consensus 78c »

Reports Q1 revenue $2.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

BWA

BorgWarner

$43.50

-0.135 (-0.31%)

06:34
04/25/19
04/25
06:34
04/25/19
06:34
Earnings
BorgWarner reports Q1 adj. EPS $1.00, consensus 95c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NTDOY

Nintendo

$0.00

(0.00%)

06:33
04/25/19
04/25
06:33
04/25/19
06:33
Hot Stocks
Nintendo says sold 16.95M Switch units in FY19 »

Nintendo said: "The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

MMM

3M

$219.24

-0.28 (-0.13%)

06:33
04/25/19
04/25
06:33
04/25/19
06:33
Hot Stocks
3M to cut 2,000 positions worldwide »

Reflecting a slower than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

LLEX

Lilis Energy

$1.11

-0.045 (-3.90%)

06:32
04/25/19
04/25
06:32
04/25/19
06:32
Hot Stocks
Lilis Energy reports Q1 oil production 3,530 Bop/d »

Reports Q1 oil production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

NTDOY

Nintendo

$0.00

(0.00%)

06:32
04/25/19
04/25
06:32
04/25/19
06:32
Earnings
Breaking Earnings news story on Nintendo »

Nintendo sees FY20 profit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

TSLA

Tesla

$258.70

-5.15 (-1.95%)

06:31
04/25/19
04/25
06:31
04/25/19
06:31
Recommendations
Tesla analyst commentary at Piper Jaffray »

Tesla's 'nasty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$219.24

-0.28 (-0.13%)

06:31
04/25/19
04/25
06:31
04/25/19
06:31
Earnings
Breaking Earnings news story on 3M »

3M cuts FY19 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

NTDOY

Nintendo

$0.00

(0.00%)

06:31
04/25/19
04/25
06:31
04/25/19
06:31
Earnings
Nintendo reports FY profit per share Y1,615.51 vs. Y1,1623.30 last year »

Reports FY revenue Y1.2T…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

MMM

3M

$219.24

-0.28 (-0.13%)

06:30
04/25/19
04/25
06:30
04/25/19
06:30
Earnings
3M reports Q1 adjusted EPS $2.23, consensus $2.49 »

Reports Q1 revenue $7.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

NSANY

Nissan

$0.00

(0.00%)

06:29
04/25/19
04/25
06:29
04/25/19
06:29
Periodicals
Carlos Ghosn granted bail in Tokyo for second time, WSJ reports »

Former Nissan chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPH

TRI Pointe

$14.27

0.12 (0.85%)

06:28
04/25/19
04/25
06:28
04/25/19
06:28
Hot Stocks
TRI Pointe sees 2019 homebuilding gross margin 19%-20% »

Reiterates its previous…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

BCS

Barclays

$8.51

-0.085 (-0.99%)

06:28
04/25/19
04/25
06:28
04/25/19
06:28
Hot Stocks
Barclays continues to target 2019 RoTE of greater than 9% »

Barclays continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    Jun

TPH

TRI Pointe

$14.27

0.12 (0.85%)

06:27
04/25/19
04/25
06:27
04/25/19
06:27
Hot Stocks
TRI Pointe sees Q2 homebuilding gross margin 17% »

For Q2, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

BCS

Barclays

$8.51

-0.085 (-0.99%)

06:27
04/25/19
04/25
06:27
04/25/19
06:27
Earnings
Barclays reports Q1 adjusted basic EPS 6.3p vs. 7.1p last year »

Barclays Group profit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    Jun

CMG

Chipotle

$710.00

7.61 (1.08%)

06:27
04/25/19
04/25
06:27
04/25/19
06:27
Recommendations
Chipotle analyst commentary at Piper Jaffray »

Piper Jaffray boosts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

APC

Anadarko

$71.41

7.29 (11.37%)

06:26
04/25/19
04/25
06:26
04/25/19
06:26
Downgrade
Anadarko rating change at Scotiabank »

Anadarko downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 22

    May

OC

Owens Corning

$52.48

-3.12 (-5.61%)

06:26
04/25/19
04/25
06:26
04/25/19
06:26
Downgrade
Owens Corning rating change at Seaport Global »

Owens Corning downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.